Parkinson-Plus Syndromes: Clinical Features, Diagnosis, and Management
Parkinson-plus syndromes—including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD)—are atypical parkinsonisms that present with bradykinesia and rigidity plus additional distinguishing features, and MRI brain without contrast is the essential initial imaging study to differentiate these conditions from idiopathic Parkinson's disease. 1
Key Clinical Features by Syndrome
Progressive Supranuclear Palsy (PSP)
PSP is the most common atypical parkinsonism with prevalence around 5/100,000. Look for these specific red flags: 1
- Age of onset: Sixth or seventh decade (mean age 63)
- Cardinal early feature: Unexplained falls due to lurching gait and axial dystonia
- Eye findings: Blurred vision and slow saccades appear early; vertical supranuclear gaze palsy typically emerges later in disease course
- Pathology: Tauopathy with abnormal tau protein accumulation
Critical pitfall: The classic vertical gaze palsy is often absent early, so don't wait for this sign to make the diagnosis—focus on the falls and axial rigidity pattern.
Multiple System Atrophy (MSA)
MSA presents between ages 55-65 with mean disease duration of 6 years. Three clinical subtypes exist: 1
- MSA-P (striatonigral degeneration): Extrapyramidal/Parkinsonian features predominate
- MSA-C (olivopontocerebellar atrophy): Cerebellar ataxia dominates
- MSA-A (Shy-Drager syndrome): Autonomic dysfunction is primary (less common)
Key distinguishing features across all subtypes:
- Cerebellar ataxia
- Pyramidal signs
- Dysautonomia—particularly urinary incontinence (this is a major differentiator from PD)
- Pathology: Synucleinopathy with abnormal cytoplasmic inclusions of ubiquitin and alpha-synuclein in oligodendroglia
Corticobasal Degeneration (CBD)
CBD presents between ages 50-70 with distinctive asymmetric features: 1
- Initial presentation: Asymmetric limb clumsiness
- Motor features: Unilateral limb rigidity and dystonia, including the pathognomonic "alien limb phenomenon"
- Cortical features: Apraxia, cortical dementia, cortical sensory deficits, impaired language production
- Postural imbalance
- Pathology: Tauopathy (like PSP)
Diagnostic Work-Up Algorithm
Step 1: Clinical Recognition
All Parkinson-plus syndromes share: bradykinesia and rigidity (the parkinsonian features), but diagnosis hinges on identifying the "plus" features described above. 1
Major clinical red flags suggesting atypical parkinsonism rather than PD:
- Symmetrical onset
- Prominent axial (not limb) rigidity
- Early postural instability and falls
- Poor or absent levodopa response
- Early autonomic failure
- Supranuclear gaze abnormalities
Step 2: Initial Imaging—MRI Brain Without Contrast
This is the cornerstone imaging study and is usually appropriate for all suspected Parkinson-plus syndromes. 1 MRI demonstrates characteristic patterns of regional atrophy:
- PSP: Midbrain atrophy with characteristic imaging findings
- MSA: Patterns vary by subtype (putaminal changes in MSA-P, pontocerebellar atrophy in MSA-C)
- CBD: Asymmetric cortical atrophy
CT head is not preferred due to limited soft-tissue characterization, though it can demonstrate atrophy patterns and exclude structural lesions or vascular disease. 1
Step 3: Functional Imaging for Specific Scenarios
I-123 Ioflupane SPECT/CT (DaTscan):
- Use this to differentiate Parkinson-plus syndromes from essential tremor and drug-induced tremor 1
- Shows abnormal dopaminergic depletion in PD, MSA, PSP, and CBD
- Critical point: A normal DaTscan essentially excludes all parkinsonian syndromes
- Limitation: Cannot distinguish between PD and Parkinson-plus syndromes (all show abnormality)
FDG-PET/CT Brain:
- Limited evidence but useful for discriminating PSP from idiopathic PD 1
- PSP shows characteristic hypometabolism in medial frontal and anterior cingulate cortices, striatum, and midbrain
- Not present in typical PD
Amyloid PET/CT: No role in Parkinson-plus syndrome evaluation 1
Treatment Approach
The harsh reality: No disease-modifying treatments exist for any Parkinson-plus syndrome, and prognosis is significantly worse than idiopathic PD. 2, 3, 4
Symptomatic Management Strategy
Levodopa trial is mandatory but expectations must be realistic:
- PSP and MSA show poor or minimal response to levodopa (unlike PD's excellent sustained response)
- CBD typically shows poor levodopa response
- Still attempt a trial as occasional patients derive modest benefit
Multidisciplinary team approach is essential: 2
- Physical therapy for gait and balance (especially critical in PSP with early falls)
- Occupational therapy for activities of daily living
- Speech therapy for dysarthria and dysphagia
- Management of autonomic dysfunction in MSA (orthostatic hypotension, urinary symptoms)
Disease-specific considerations:
- MSA autonomic symptoms: Treat orthostatic hypotension with fludrocortisone, midodrine; manage urinary dysfunction
- PSP falls: Aggressive fall prevention strategies, walker/wheelchair earlier than typical PD
- CBD cognitive/cortical symptoms: Supportive care for apraxia and dementia
Prognosis Counseling
Mean disease duration for MSA is approximately 6 years. PSP and CBD have similarly poor prognoses compared to PD, which typically spans 10-20+ years. Early discussion of prognosis and advance care planning is appropriate. 1
Critical Diagnostic Pitfalls to Avoid
Don't wait for "classic" late signs (like vertical gaze palsy in PSP) to make the diagnosis—early recognition based on falls, axial rigidity, and poor levodopa response is key
Symmetrical onset and early falls are major red flags that should immediately raise suspicion for atypical parkinsonism rather than PD
Prominent early autonomic dysfunction, especially urinary incontinence, strongly suggests MSA over PD
The "alien limb phenomenon" is pathognomonic for CBD—don't miss this distinctive feature
Clinical diagnosis alone is challenging—imaging is essential and not optional 1